Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial

IMPORTANCE: Controlled clinical laboratory studies have shown that cannabidiol (CBD) can sometimes attenuate or exacerbate the effects of Δ9-tetrahydrocannabinol (Δ9-THC). No studies have evaluated differences in pharmacokinetics (PK) of Δ9-THC and pharmacodynamics (PD) between orally administered c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamarripa, C. Austin, Spindle, Tory R., Surujunarain, Renuka, Weerts, Elise M., Bansal, Sumit, Unadkat, Jashvant D., Paine, Mary F., Vandrey, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926328/
https://www.ncbi.nlm.nih.gov/pubmed/36780161
http://dx.doi.org/10.1001/jamanetworkopen.2022.54752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926328/
https://www.ncbi.nlm.nih.gov/pubmed/36780161
http://dx.doi.org/10.1001/jamanetworkopen.2022.54752

Ejemplares similares